Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Novartis said pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce the risk of cardiovascular events versus placebo, including deaths, heart attacks and strokes.
Novartis said its heart disease drug pelacarsen did not meet the primary endpoint in a Phase 3 study, failing to reduce cardiovascular events versus placebo.